Calidi Biotherapeutics is using the lead-up to AACR 2026 to showcase a new approach to solid tumor immunotherapy centered on in situ T-cell engagers.
On April 1, 2026, the company announced that it will present new data at the American Association of Cancer Research annual meeting, including a new candidate targeting TROP-2 and a platform strategy designed to activate T cells while inducing T-cell engager expression directly in the tumor microenvironment.
Read a preview on ACCR Annual Meeting 2026 on OncoDaily.
View and add the event to your calendar from OncoCalendar.
The technology behind this update is Calidi’s RedTail platform, a systemically delivered virotherapy platform that the company says is designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Calidi’s lead RedTail-derived candidate, CLD-401, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known activator of T cells and natural killer cells in the tumor microenvironment.
Calidi’s AACR 2026 preview expands on preclinical data the company had already shared at the AACR Immuno-Oncology Conference in February 2026. At that meeting, Calidi said its RedTail viruses were able to express both a functional bispecific T-cell engager (BiTE) and IL-15 SA at high concentrations within tumors, creating the possibility of simultaneously altering the tumor microenvironment, activating T cells, and enabling tumor-localized immune targeting.
That idea addresses a central limitation in cancer immunotherapy. T-cell engagers have shown strong activity in hematologic malignancies, but they have historically struggled in solid tumors where the tumor microenvironment suppresses immune-cell infiltration and T-cell activity. Calidi’s strategy is to turn the tumor itself into a localized producer of both immune activators and tumor-targeting engagers, potentially helping overcome one of the major barriers that has limited this class in solid cancers.
The addition of TROP-2 as a highlighted target is also notable. TROP-2 is a recognized solid tumor target, but it has been challenging because expression in normal tissue raises the risk of off-tumor, on-target toxicity. Calidi says its RedTail approach may help reduce that concern by confining T-cell engager expression to the tumor microenvironment instead of relying on broad systemic exposure. The company also said it is exploring additional targets, including EGFR, EpCAM, and Nectin-4.
Beyond the AACR presentation, Calidi is also advancing CLD-401 toward the clinic. On March 24, 2026, the company announced a partnership with Avance Clinical aimed at rapidly initiating a first-in-human clinical trial for CLD-401 in Australia, while also pursuing an FDA IND filing in 2026. Calidi said the planned Phase 1 study will evaluate safety, pharmacodynamics, and efficacy in patients with solid tumors who have exhausted available therapeutic options.
In a March 27, 2026 corporate update, Calidi said it had also received FDA feedback through Type D interactions that it believes supports its manufacturing and analytical approach for CLD-401. The company reiterated that it expects to file an IND by the end of 2026 and highlighted both its partnership with Matica Bio for GMP manufacturing and its expanding in situ T-cell engager work as part of RedTail’s broader platform potential.
This story stands out because it combines two strong themes: AACR momentum and next-generation solid tumor immunotherapy. While the current data remain preclinical, Calidi is positioning RedTail as more than a single-asset platform by showing how it might support tumor-localized cytokine delivery, in situ T-cell engager expression, and a wider range of solid tumor targets in the future.
Read more biotech insights on OncoDaily Biotech.